Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2016 | Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations | Cheng Y.; Murakami H; PAN-CHYR YANG ; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG | Journal of Clinical Oncology | 160 | 134 | |
2017 | Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al | CHIH-HSIN YANG ; Puri T; Orlando M; Cheng Y. | Journal of Clinical Oncology | 0 | 0 | |
2018 | A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer | CHIH-HSIN YANG ; Mok T; Han B; Orlando M; Puri T; Park K. | Clinical Lung Cancer | 18 | 17 |